Table 1 Characteristics of studies included based on treatment regimens: cisplatin in monotherapy
|  | Affiliation | Type of study | Stage of disease | Nº of BRCA1/2 mutated TNBC patients | pCR | Neoadjuvant treatment (Cisplatin 75 mg/m2) |
|---|---|---|---|---|---|---|
Silver, 2010 [30] | USA | Clinical Trial | II-III | 2 | 2 | Cis |
Byrski, 2014 [18] | Poland | Clinical Trial | I-III | 86 | 52 | Cis |
Kolacinka, 2012 [31] | Poland | Clinical Trial | II-III | 1 | 1 | Cis |
Moiseyenko, 2015 [32] | Russia | Case series | II-III | 6 | 3 | Cis |
Tung, 2020 [33] ( TBCRC 031) | USA | RCT Phase II | II-III | 44 | 10 | Cis |